BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 18, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will present at
two upcoming investor conferences:

Live audio webcasts of the presentations can be accessed through the
Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on the
Company's website for two weeks following each presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis, and in Phase 2
clinical development for inflammatory dry eye disease. An NDA for the
post-operative ocular pain indication has been accepted by the FDA with
a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being
conducted for post-operative ocular inflammation and pain. For glaucoma
and ocular hypertension, OTX-TP (sustained release travoprost)
intracanalicular depot, has completed a Phase 2b clinical trial. Ocular
Therapeutix is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.